Secretory Phospholipase A2 Inhibition Attenuates Adhesive Properties of Esophageal Barrett's Cells

J Surg Res. 2021 Mar:259:562-568. doi: 10.1016/j.jss.2020.10.018. Epub 2020 Nov 28.

Abstract

Background: Gastroesophageal reflux and Barrett's esophagus are significant risk factors for the development of esophageal adenocarcinoma. Group IIa secretory phospholipase A2 (sPLA2) catalyzes the production of various proinflammatory metabolites and plays a critical role in promoting reflux-induced inflammatory changes within the distal esophagus. We hypothesized that inhibition of sPLA2 in human Barrett's cells would attenuate adhesion molecule expression via decreased activation of nuclear factor kappa B (NF-κB) and decrease cell proliferation, possibly mitigating the invasive potential of Barrett's esophagus.

Materials and methods: Normal human esophageal epithelial cells (HET1A) and Barrett's cells (CPB) were assayed for baseline sPLA2 expression. CPB cells were treated with a specific inhibitor of sPLA2 followed by tumor necrosis factor-α. Protein expression was evaluated using immunoblotting. Cell proliferation was assessed using an MTS cell proliferation assay kit. Statistical analysis was performed using the Student's t-test or analysis of variance, where appropriate.

Results: CPB cells demonstrated higher baseline sPLA2 expression than HET1A cells (P = 0.0005). Treatment with 30 μM sPLA2 inhibitor significantly attenuated intercellular adhesion molecule-1 (P = 0.004) and vascular cell adhesion molecule-1 (P < 0.0001) expression as well as decreased NF-κB activation (P = 0.002). sPLA2 inhibition decreased cell proliferation in a dose-dependent manner (P < 0.001 for 15, 20, and 30 μM doses).

Conclusions: sPLA2 inhibition in human Barrett's cells decreases cellular adhesive properties and NF-κB activation as well as decreases cell proliferation, signifying downregulation of the inflammatory response and possible attenuation of cellular malignant potential. These findings identify sPLA2 inhibition as a potential chemopreventive target for premalignant lesions of the esophagus.

Keywords: Barrett's esophagus; Intercellular adhesion molecule-1; Proliferation; Secretory phospholipase A(2); Vascular cell adhesion molecule-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / prevention & control
  • Barrett Esophagus / drug therapy
  • Barrett Esophagus / pathology*
  • Cell Adhesion / drug effects
  • Cell Line
  • Cell Proliferation / drug effects
  • Drug Evaluation, Preclinical
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / prevention & control
  • Esophagus / cytology
  • Esophagus / pathology*
  • Group II Phospholipases A2 / antagonists & inhibitors*
  • Group II Phospholipases A2 / metabolism
  • Humans
  • Pentanoic Acids / pharmacology*
  • Pentanoic Acids / therapeutic use

Substances

  • 5-(4-benzyloxyphenyl)-4S-(7-phenylheptanoylamino)pentanoic acid
  • Pentanoic Acids
  • Group II Phospholipases A2

Supplementary concepts

  • Adenocarcinoma Of Esophagus